On 12 September 2024, Ono Pharmaceutical and Bristol-Myers Squibb announced they submitted a supplemental application in Japan for Ono’s Opdivo® (nivolumab) and BMS’s Yervoy® (ipilimumab) in combination therapy, to expand use to unresectable advanced or recurrent microsatellite instability-high (MSI-High) colorectal cancer.
This follows an August 2024 application in Japan for the same combination for unresectable hepatocellular carcinoma.